Akebia Therapeutics (NASDAQ:AKBA) Stock Price Expected to Rise, Piper Sandler Analyst Says
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) had its price objective boosted by equities researchers at Piper Sandler from $4.00 to $6.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s target price would indicate a potential upside of 165.49% from the […]
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) had its price objective boosted by equities researchers at Piper Sandler from $4.00 to $6.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Sandler’s target price would indicate a potential upside of 165.49% from the […]
